Results 51 to 60 of about 8,958 (210)

Oncolytic Virus Immunotherapy [PDF]

, 2022
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and ...

core   +1 more source

The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy

Cells, 2022
Neutrophils are innate leukocytes with diverse effector functions that allow them to respond to pathogens rapidly. Accumulating evidence has highlighted these cells’ complex roles in the host’s response to viral infections and tumor progression ...
Jessica A. Minott, Jacob P. van Vloten, Lily Chan, Yeganeh Mehrani, Byram W. Bridle, Khalil Karimi   +5 more
doaj   +1 more source

Tumor Restrictions to Oncolytic Virus

Biomedicines, 2014
Oncolytic virotherapy has advanced since the days of its conception but therapeutic efficacy in the clinics does not seem to reach the same level as in animal models.
Markus Vähä-Koskela, Ari Hinkkanen
doaj   +1 more source

Oscillation thresholds via the novel MBR method with application to oncolytic virotherapy

Nonlinear Analysis, 2022
Oncolytic virotherapy is a therapy for the treatment of malignant tumours. In some undesirable cases, the injection of viral particles can lead to stationary oscillations, thus preventing the full destruction of the tumour mass.
Bruno Buonomo, Rossella Della Marca, Salvatore Rionero   +2 more
doaj   +1 more source

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells [PDF]

, 2013
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence.
Mittelbronn, Michel Guy André, Janina Seznec, Michel Mittelbronn, Jürgen Schlegel, Surowiak, Pawel, Ulrike Naumann, Klaus Mantwill, Naumann, Ulrike, Vroni Girbinger, Per Holm, Dagmar Beier, Girbinger, Vroni, Lage, Hermann, Holm, Per Sonne, Pawel Surowiak, Hermann Lage, Schlegel, Jürgen, Beier, Dagmar, Seznec, Janina, Mantwill, Klaus   +19 more
core   +1 more source

Targeting tumor vasculature through oncolytic virotherapy: recent advances

, 2015
The oncolytic virotherapy field has made significant advances in the last decade, with a rapidly increasing number of early- and late-stage clinical trials, some of them showing safety and promising therapeutic efficacy.
Merchan, Jaime R, Toro Bejarano, Marcela   +1 more
core   +1 more source

Progress of oncolytic virotherapy for neuroblastoma

Frontiers in Pediatrics, 2022
As a neuroendocrine tumor derived from the neural crest, neuroblastoma (NB) is the most common extracranial solid tumor in children. The prognosis in patients with low- and intermediate-risk NB is favorable while that in high-risk patients is often detrimental.
Xiao-Tong Chen, Shu-Yang Dai, Yong Zhan, Ran Yang, De-Qian Chen, Yi Li, En-Qing Zhou, Rui Dong   +7 more
openaire   +3 more sources

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

, 2020
PURPOSE OF REVIEW: To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatment in vitro in human CHST cells and in a gerbil CHST model. RECENT
Brian R. Earl, Ravi N. Samy, Lipschitz, Noga, Samy, Ravi N, MD, Earl, Brian R, Timothy P. Cripe, Noga Lipschitz, Cripe, Timothy P   +7 more
core   +1 more source

Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas

Frontiers in Neurology
High-grade gliomas (HGG) such as glioblastoma are the most aggressive primary malignancies of the central nervous system. The median overall survival of glioblastoma is <15 months despite treatment with surgery, radiotherapy, and chemotherapy ...
Zhihong Qian, Qiang Gao, Wei Zhang, Wei Zhang, Wei Zhang   +4 more
doaj   +1 more source